
Weekly Roundup: January 10-14
ICYMI, this week we had stories on Vial's CRO launch, our conference coverage coming up this weekend, and more.
Taking a broader look at moderate to severe plaque psoriasis, experts consider what the standard of care would be in different settings.
A brief review of biologic agents being used or evaluated in the setting of plaque psoriasis.
The new year promises to be rich with dermatology game changers following a sluggish 2021 for breakthroughs and FDA approvals.
Lubriderm and the National Hispanic Health Foundation collaborate on the Skin Scholarship sponsored by Lubriderm to help increase United States Hispanic representation and accessibility in dermatology.
A national survey found that patients are willing to try medical cannabis products as potential treatments of their condition. Additionally, some already use over-the-counter cannabis products.
In this week’s Pointers with Dr Portela, the 208SkinDoc discusses the story of how a hockey fan spotted a cancerous mole on the on the Canucks, a National Hockey League (NHL) Team, equipment manager.
In this month's Cosmetic Conundrums, Zoe Diana Draelos, MD, an adjunct assistant professor of dermatology at Duke University School of Medicine in Durham, North Carolina, and chief medical editor of Dermatology Times®, tackles cosmetic box claims and what exactly 'sensitive skin' means in the cosmetic world.
Vial launches Vial Dermatology contract research organization (CRO) and highlights how it could improve the speed and quality of clinical trials.
This episode of The Cutaneous Connection podcast, explores hair loss and hair treatment of patients with textured or tightly coiled hair. Candrice Heath, MD, FAAP, FAAD a dermatologist and assistant professor of dermatology at the Lewis Katz School of Medicine at Temple University, explains her experience and highlights how all dermatologists can improve their treatment plans.
Energy and autos lead the way, health care relatively stable.
But protection against hospitalization and death remain strong.
A pharmaceutical company that wants to work with him on COVID-19–related dermatoses contacts his research nurse and asks for a copy of all this electronic data since the pandemic started in March 2020, which would allow them to develop better treatments for unusual dermatoses. Trying to be helpful, the nurse gives them the data.
Several talks expected to focus on the latest treatment updates, as well as some recently published data on COVID-19 symptoms and a commonly-used atopic dermatitis treatment.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


















